title: Does immunological status affect the prevalence of Hepatitis C virus infection among HIV/AIDS patients?
abstract: BACKGROUND
  Even though HIV-HCV co-infection rates vary widely according to western reports, not so much has been documented about the situation in our environment. We determined the prevalence of HCV among our HIV cohort as well as described the relationship between the immune and virological status of the patients in this report.
  
  
  METHODS
  Data of 1044 consenting HIV infected patients (confirmed by Western blot assay) receiving treatment at our centre between Sep 2002 and Feb 2005 were analyzed using EpiInfo 2004 retrospectively. The sera of the patients were used to determine their anti-HCVstatus by third generation ELISA (DIA.PRO Diagnostic, Bioprobes srl, Italy). HIV RNA levels and CD4 cell counts were also determined at recruitment by Roche Amplicor 1.5 and Flow Cytometry (Partec, Germany).
  
  
  RESULTS
  Ninety out of 1044 patients (8.6%) were positive for anti-HCV The rate of co-infection was highest among the divorced (10.3%), followed by widows (9.9%) though this did not reach statistical significance. The odds of finding anti-HCV was more than twice with CD4 cell counts >600 cells/microlitre compared to below 200 cells/microlitre (p=0.026). The median HIV RNA levels of HCV co-infected individuals was 514 copies/ml, while it was 200 copies/ml for HIV monoinfected persons (p>0.05).
  
  
  CONCLUSIONS
  The prevalence of HCV among this HIV cohort is high. There is also an associated higher chance of detecting anti-HCV in sera of the HIV patients whose immunological status is better than severely immunocompromised individuals.
authors.affiliation: Jos University Teaching Hospital/AIDS Prevention Initiative in Nigeria (APIN)/Presidential Emergency Plan For AIDS Relief (PEPFAR) Project, APIN Centre, JUTH/University of Jos, Nigeria. nimzing@yahoo.com
authors.forename: N G
authors.initials: NG
authors.lastname: Ladep
authors.forename: O
authors.initials: O
authors.lastname: Agbaji
authors.forename: P
authors.initials: P
authors.lastname: Agaba
authors.forename: P
authors.initials: P
authors.lastname: Badung
authors.forename: G
authors.initials: G
authors.lastname: Imade
authors.forename: J
authors.initials: J
authors.lastname: Sankalé
authors.forename: J
authors.initials: J
authors.lastname: Idoko
authors.forename: P
authors.initials: P
authors.lastname: Kanki
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000276:immunology; D006304:Health Status; D006526:Hepatitis C / Q000453:epidemiology* / Q000209:etiology / Q000276:immunology; D006801:Humans; D016867:Immunocompromised Host; D008297:Male; D008875:Middle Aged; D009549:Nigeria / Q000453:epidemiology; D015995:Prevalence; D012189:Retrospective Studies; D012307:Risk Factors